DeCure for Ectrodactyly, ectodermal dysplasia, and cleft lip-palate syndrome 3
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for ectrodactyly, ectodermal dysplasia, and cleft lip-palate syndrome 3 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEctrodactyly, ectodermal dysplasia, and cleft lip-palate syndrome 3 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ectrodactyly, ectodermal dysplasia, and cleft lip-palate syndrome 3 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
tumor protein p63 (TP63) — TP63 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7Z7E · 1.8 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
No drug treatment is described in any of these abstracts. The six case reports (2006, 2012, 2012, 2015, 2021, 2011) all describe the same rare syndrome — ectrodactyly, ectodermal dysplasia, and cleft lip/palate (EEC) — and each notes that the syndrome is autosomal dominant with variable expression and reduced penetrance. The 2006 report describes a 44-month-old girl who had features of EEC syndrome but without the classic ectrodactyly. The 2012 "incomplete syndrome" report describes a case with ectrodactyly and cleft lip and palate but absence of signs of ectodermal dysplasia, and also notes syndactyly of toes as a rarely reported feature. The other 2012 report describes a 40-year-old male who had ectrodactyly and ectodermal dysplasia but no clefting of lips or palate. The 2015 report describes a 22-year-old boy, the 2021 report a 3-month-old girl, and the 2011 report a neonate whose mother and two siblings were also affected.
No abstract reports any therapeutic intervention, drug trial, or outcome data such as survival or response rates. The management described in the 2012 "incomplete syndrome" report is a multidisciplinary approach coordinated by a pedodontist or paediatrician. The 2015 and 2021 reports both state that management is challenging and that there are few reports in the medical literature. The 2011 report notes familial clustering but offers no treatment.
What is missing is any clinical trial, any drug tested in EEC syndrome, any quantitative outcome data, and any funded research programme aimed at pharmacological intervention. The literature consists entirely of single-case descriptions. Without a trial design, patient stratification, and funding for a therapeutic study, no evidence exists for any drug in this condition.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Ectodermal dysplasia, ectrodactyly, cleft lip/palate syndrome without ectrodactyly
AbstractThe ectodermal dysplasia, ectrodactyly, cleft lip/palate syndrome (EEC syndrome) is an autosomal dominant dysplasia syndrome, whose pleiotropic effects involve mainly ectodermal structures. The most common clinical manifestations are ectodermal dysplasia, ectrodactyly , cleft lip/palate, and tear-duct anomalies. Very rarely the ectrodactyly may be absent, and skeletal abnormalities may be subtle. We present a 44-month-old girl who had features of EEC syndrome but without the classic ectrodactyly.
Ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome: A case report of "Incomplete syndrome"
AbstractEctrodactyly, ectodermal dysplasia, and cleft lip/palate (EEC) is a rare syndrome having ectrodactyly, ectodermal dysplasia, and cleft lip/palate. So far, very few cases have been reported in literature. However, we report a case of incomplete EEC syndrome having ectrodactyly and cleft lip and palate with absence of signs of ectodermal dysplasia with no other systemic anomalies. Other feature noted is the syndactyly of toes which is reported rarely in this syndrome. A multidisciplinary approach for treatment is needed which is co-ordinated by pedodontist or pediatrician.
Ectrodactyly, Ectodermal dysplasia, and Cleft lip-palate (EEC) syndrome without clefting: A rare case report
AbstractEctrodactyly, Ectodermal dysplasia, and Cleft lip-cleft palate (EEC) syndrome is a rare ectodermal dysplasia presenting with various combinations of its three components. It is an autosomal dominant disorder with variable expression and penetrance. Patients have features of ectodermal abnormalities and a split hand/foot deformity of the limbs. We report a case of this rare disorder in a 40-year-old male who had ectrodactyly, ectodermal dysplasia, but no clefting of lips or palate.
Plastic and Aesthetic Research · 2015 · 2 citations · open access
Ectrodactyly-ectodermal dysplasia-cleft lip/palate syndrome: a rare entity
AbstractEctrodactyly-ectodermic dysplasia-cleft lip/palate (EEC) syndrome is a rare congenital anomaly of inherited origin and varying clinical features. This syndrome has three main symptoms, which display variable expression and penetrance. The management of this syndrome is challenging, with few reports in the medical literature. We present a case of a 22-year-old boy with EEC syndrome and offer insight into current knowledge about this syndrome.
AbstractEctrodactyly–ectodermal dysplasia–clefting (EEC) syndrome is a rare hereditary congenital defect characterized by a triad of disorders such as ectodermal dysplasia, malformed extremities, and cleft lip and/or palate. We report the case of a 3-month-old girl child with clinical signs of EEC syndrome and offer valuable information into current knowledge about this syndrome. The symptoms of EEC display diversity in both extension and expression. Early diagnosis and management of clinical manifestations associated with this syndrome presents a unique challenge due to the paucity of documents in the literature.
Indian journal of human genetics · 2011 · 0 citations
Familial clustering of a rare syndrome
AbstractEctrodactyly, ectodermal dysplasia and cleft palate syndrome is a rare autosomal dominant multiple congenital anomaly syndrome with variable expressivity and reduced penetration. The cardinal features are cleft palate/lip, lobster hand deformity, sparse hypopigmented hair, dry scaly skin, and lacrimal and urogenital anomalies. A neonate presented to us with typical features, his mother and other two siblings were also affected.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
